GSK Paxil CR Ad Medicalizes "Ordinary" Anxiety, FDA Says
This article was originally published in The Pink Sheet Daily
TV ads "broaden" use of the antidepressant beyond social anxiety disorder and into attributes that "do not generally require psychopharmacological treatment," FDA ad division letter says. Risk information is minimized by distractions and failure to note contraindications, FDA says.
You may also be interested in...
The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.
The ad division letter follows an Office of Personnel Management Inspector General investigation into Wyeth's Effexor marketing practices. FDA asserts that Wyeth's claims of superiority to SSRIs are unsubstantiated.
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.